311 related articles for article (PubMed ID: 30836812)
21. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
22. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
23. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
Grimm MO; Schostak M; Grün CB; Loidl W; Pichler M; Zimmermann U; Schmitz-Dräger B; Steiner T; Roghmann F; Niegisch G; Bolenz C; Schmitz M; Baretton G; Leucht K; Schumacher U; Foller S; Zengerling F; Meran J;
JAMA Oncol; 2024 Jun; 10(6):755-764. PubMed ID: 38722641
[TBL] [Abstract][Full Text] [Related]
24. Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data.
Niegisch G; Grimm MO; Hardtstock F; Krieger J; Starry A; Osowski U; Deiters B; Maywald U; Wilke T; Kearney M
J Med Econ; 2024; 27(1):531-542. PubMed ID: 38639988
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
26. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
27. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.
Mato A; Nabhan C; Lamanna N; Kay NE; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Swern AS; Sullivan K; Flick ED; Gressett Ussery SM; Gharibo M; Kiselev P; Sharman JP
Blood Adv; 2020 Apr; 4(7):1407-1418. PubMed ID: 32271900
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
Porte F; Granghaud A; Chang J; Kearney M; Morel A; Plessala I; Cawston H; Roiz J; Xiao Y; Solbes MN; Lambert P; Ravaud A; Loriot Y; Thiery-Vuillemin A; Lévy P
PLoS One; 2024; 19(5):e0302548. PubMed ID: 38728337
[TBL] [Abstract][Full Text] [Related]
29. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
30. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
Huang SY; Wu CC; Hsieh MC; Rau KM; Chiang PH; Sung MT; Luo HL; Huang CC; Huang CH; Liu JM; Su HY
Oncology; 2020; 98(3):146-153. PubMed ID: 31794969
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.
Ranganathan S; Riveros C; Xu J; Hu S; Geng M; Huang E; Melchiode Z; Zhang J; Efstathiou E; Chan KS; Wallis CJD; Sonpavde G; Satkunasivam R
Urol Oncol; 2024 Sep; 42(9):291.e13-291.e25. PubMed ID: 38763801
[TBL] [Abstract][Full Text] [Related]
32. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
33. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison.
Nordstrom BL; Oguz M; Chu BC; Ouwens M; Arkenau HT; Klein AB
J Comp Eff Res; 2020 Feb; 9(3):191-199. PubMed ID: 31916448
[No Abstract] [Full Text] [Related]
35. Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting.
Simeone JC; Nordstrom BL; Patel K; Mann H; Klein AB; Horne L
Cancer Epidemiol; 2019 Jun; 60():121-127. PubMed ID: 30953972
[TBL] [Abstract][Full Text] [Related]
36. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
37. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
Gupta S; Andreev-Drakhlin A; Fajardo O; Fassò M; Garcia JA; Wee C; Schröder C
J Natl Cancer Inst; 2024 Apr; 116(4):547-554. PubMed ID: 38036464
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy.
Kebede N; Shah R; Shah A; Corman S; Nwankwo C
Future Oncol; 2022 Mar; 18(8):953-964. PubMed ID: 35094566
[No Abstract] [Full Text] [Related]
39. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT
Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
